NCCN

PatientPoint Brings NCCN Resources for Patients to Oncology Practices Nationwide

Retrieved on: 
Dienstag, Februar 6, 2024
Research, Caregiver, Patient, NCCN, Education, Health, Cancer

CINCINNATI, Feb. 6, 2024 /PRNewswire/ -- PatientPoint® today announced a new collaboration with the NCCN Foundation® to expand use of NCCN Guidelines for Patients® in oncology practices nationwide. The collaboration leverages the PatientPoint digital patient engagement platform to bring trustworthy patient education materials on common cancer types to people with cancer, providers and caregivers in the exam room.

Key Points: 
  • CINCINNATI, Feb. 6, 2024 /PRNewswire/ -- PatientPoint® today announced a new collaboration with the NCCN Foundation® to expand use of NCCN Guidelines for Patients® in oncology practices nationwide.
  • The NCCN Guidelines for Patients are created and maintained by the National Comprehensive Cancer Network® (NCCN®) , a not-for-profit alliance of 33 leading cancer centers devoted to patient care, research and education.
  • The NCCN Guidelines for Patients have been independently recognized for their ability to empower people with cancer and caregivers.
  • As part of the PatientPoint-NCCN collaboration, PatientPoint will include NCCN Guidelines for Patients on the following cancer types alongside its award-winning oncology education:

Goserelin Dosing Options Included in the National Comprehensive Cancer Network® (NCCN) Breast Cancer Guidelines

Retrieved on: 
Montag, Februar 5, 2024
Oncology, Health, FDA, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Breast cancer, Division, Goserelin, MD, NCCN, Safety, Patient, HR, Therapy, Hematology, University, Woman, Birth control

The inclusion of goserelin 10.8 mg every 12 weeks in the breast cancer guidelines as a method for ovarian function suppression is a category 2A recommendation.

Key Points: 
  • The inclusion of goserelin 10.8 mg every 12 weeks in the breast cancer guidelines as a method for ovarian function suppression is a category 2A recommendation.
  • Multiple international studies have evaluated the safety and efficacy of goserelin 10.8 mg every 12 weeks for ovarian function suppression in premenopausal patients with HR+ breast cancer.2-5
    In the United States, ZOLADEX® (goserelin implant) 3.6 mg is the only dosage form approved for use in breast cancer.
  • ZOLADEX 10.8 mg is not approved by FDA for breast cancer.
  • Additionally, ZOLADEX 10.8 mg is approved for use in breast cancer in over 60 countries, with multiple additional regulatory reviews underway.

For World Cancer Day, Alliance for Cancer Care Equity Advocates to 'Close the Care Gap' as Observance is Honored with Congressional Resolution

Retrieved on: 
Donnerstag, Februar 1, 2024
ACCE, Policy, Congress, Legislation, MD, NCCN, Gender identity, Diagnosis, Longevity, FDA, Lung cancer, Skin, Food, CMS, World Cancer Day, ACS, Cancer, Medicare, Pharmaceutical industry

WASHINGTON, Feb. 1, 2024 /PRNewswire/ -- For World Cancer Day, the National Comprehensive Cancer Network® (NCCN®), American Cancer Society Cancer Action Network (ACS CAN), and the National Minority Quality Forum (NMQF) are announcing three key areas of policy focus as part of the Alliance for Cancer Care Equity (ACCE) joint collaboration, including advancing diversity in clinical trials, improving cancer screening and early detection, and increasing access to patient navigation. The organizations are also working with Congresswoman Terri Sewell (D-AL) to observe the day with a congressional resolution.

Key Points: 
  • "Improving diversity in clinical trials is fundamental to advance cancer care.
  • We also know that disparities in access to screening lead to later stage at diagnosis, resulting in unequal outcomes and reduced longevity in marginalized populations.
  • The ACCE grew out of the joint Elevating Cancer Equity initiative, first launched by NCCN, ACS CAN, and NMQF in 2021.
  • Visit NCCN.org/wcd to learn more about World Cancer Day and the ACCE's efforts.

New Study Highlights Significant Potential Medicare Savings Through Use of Castle Biosciences’ DecisionDx®-SCC Test to Guide Adjuvant Radiation Therapy Decisions in Patients with Cutaneous Squamous Cell Carcinoma

Retrieved on: 
Donnerstag, Januar 18, 2024
Oncology, Health, Other Health, Other Science, Research, Science, Biotechnology, Neoplasm, National Comprehensive Cancer Network, Radiation therapy, Patient, Lymph node, Medicare, AAD, American Academy, Society, SCC, Metastasis, Journal, NCCN, ART, ASTRO

While ART can benefit some patients, selecting patients based upon clinicopathologic factors alone can lead to overtreatment of certain patients who may not experience disease progression.

Key Points: 
  • While ART can benefit some patients, selecting patients based upon clinicopathologic factors alone can lead to overtreatment of certain patients who may not experience disease progression.
  • In the study, normalized medical claims data identified 22,917 Medicare-eligible SCC patients in the United States who received ART in the 12 months ending June 2022.
  • Results from the study indicate that using the DecisionDx-SCC test to guide decisions about ART could result in net Medicare healthcare savings of up to approximately $972 million annually.
  • This outcome is based on the distribution of DecisionDx-SCC test results reported in previous studies, with cost reductions attributed to avoiding ART in patients with a DecisionDx-SCC low-risk, Class 1 test result and low rates of disease progression.

ChromaCode Announces Publication of New Study Demonstrating the Superior Performance of its HDPCR NSCLC Assay Compared to NGS with Low Sample Input

Retrieved on: 
Freitag, Januar 26, 2024
NGS, National Comprehensive Cancer Network, Patient, Glioma, DNA, RNA, PPA, Diagnosis, Cholangiocarcinoma, Genomics, NCCN, Lung cancer, Guideline, Thyroid, Medical imaging

ChromaCode's HDPCR technology helps to address low sample input, which is a common issue with core biopsy specimens used in the diagnosis of non-small cell lung cancer (NSCLC) and other tumor types.

Key Points: 
  • ChromaCode's HDPCR technology helps to address low sample input, which is a common issue with core biopsy specimens used in the diagnosis of non-small cell lung cancer (NSCLC) and other tumor types.
  • The HDPCR NSCLC Panel is an ideal test for National Comprehensive Cancer Network (NCCN) guideline directed clinically relevant variants.
  • "We have leveraged our HDPCR technology to build a rapid and cost-effective first line assay in NSCLC, covering 99.6% of prevalent NCCN variants.
  • The findings suggest that HDPCR emerges as a precise and efficient approach for identifying clinically relevant NSCLC mutations, even with low nucleotide input and quality.

Dignitana signs OncoMedical for distribution in Switzerland and Liechtenstein

Retrieved on: 
Montag, Januar 15, 2024
National Comprehensive Cancer Network, Patient, Prostate cancer, Health, Attention, Palliative care, Cancer Australia, Breast cancer, ESMO, Cancer, Scalp, Quality of life, NCCN, FDA, Hair loss, Breast, Prostate, Oncology

LUND, Sweden, Jan. 15, 2024 /PRNewswire/ -- Scalp cooling innovator Dignitana AB has signed OncoMedical AG as the exclusive distributor for The DigniCap Scalp Cooling System in Switzerland and Liechtenstein.

Key Points: 
  • LUND, Sweden, Jan. 15, 2024 /PRNewswire/ -- Scalp cooling innovator Dignitana AB has signed OncoMedical AG as the exclusive distributor for The DigniCap Scalp Cooling System in Switzerland and Liechtenstein.
  • Switzerland is a strong market for scalp cooling with many options for quality private healthcare in addition to the public sector clinics.
  • The distribution agreement with OncoMedical seeks to expand that footprint in Switzerland and Liechtenstein, while also upgrading current Dignitana customers to the advanced technology offered by the next generation DigniCap Delta system.
  • "OncoMedical shares our commitment to excellence in technology, customer service and patient care," said Catarina Löwenadler, CEO of Dignitana.

Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene

Retrieved on: 
Donnerstag, Januar 11, 2024
Neoplasm, Lasofoxifene, National Comprehensive Cancer Network, Patient, Incidence, Fulvestrant, AIS, Society, Breast cancer, Cancer, Breast, Eli Lilly, Mutation, CSCO, NCCN, Therapy, ESR1, Pharmaceutical industry

Under the terms of the agreement, Henlius will receive exclusive rights and sublicenses to lasofoxifene for at least two estrogen receptor-positive (ER+)/HER2- breast cancer indications in the territory, with Sermonix retaining all other global rights.

Key Points: 
  • Under the terms of the agreement, Henlius will receive exclusive rights and sublicenses to lasofoxifene for at least two estrogen receptor-positive (ER+)/HER2- breast cancer indications in the territory, with Sermonix retaining all other global rights.
  • Sermonix received an upfront payment and is further eligible to receive up to $58 million in certain predetermined milestones, in addition to royalties upon Henlius commercialization in China.
  • “In Phase 2 clinical trials, investigational lasofoxifene demonstrated its potential for the treatment of ER+/HER2- breast cancer harboring ESR1 mutation,” said Ping Cao, senior vice president and chief business development officer of Henlius.
  • “Lasofoxifene will play a critical role in complementing Henlius' pipeline of its breast cancer product.

ChromaCode and Tennessee Oncology Sign Early Access Agreement to Collaborate on Improving Availability of Non-Small Cell Lung Cancer Biomarker Testing

Retrieved on: 
Montag, Januar 8, 2024
RNA, Partnership, Workflow, NCCN, DNA, MD, Deletion, Genomics, Diagnosis, National Comprehensive Cancer Network, Patient, NSCLC, Personalized medicine, Medical imaging

Recently published research in the journal Diagnostics: ( https://doi.org/10.3390/diagnostics13213299) shows the remarkable sensitivity of the NSCLC assay, even with minimal input material.

Key Points: 
  • Recently published research in the journal Diagnostics: ( https://doi.org/10.3390/diagnostics13213299) shows the remarkable sensitivity of the NSCLC assay, even with minimal input material.
  • Tennessee Oncology will perform further studies to validate the analytical and clinical performance of the NSCLC kit.
  • "We conduct molecular testing for patients on a regular basis, handling over a thousand cases annually.
  • We look forward to partnering with Tennessee Oncology on our NSCLC test now and on other molecular assays in the near future," said Mark McDonough, CEO of ChromaCode.

ChromaCode Unveils ChromaCode Cloud 6.1, Showcasing Remarkable Strides in Software Innovation, Quality, and Security

Retrieved on: 
Donnerstag, Januar 4, 2024
Cloud, RNA, GDPR, Software, HITRUST, NCCN, DNA, PCR, Laboratory, HIPAA, Privacy, Genomics, National Comprehensive Cancer Network, Video game

This release marks significant progress in the development of ChromaCode's software, ensuring accessibility, affordability, and security in laboratory-based diagnostic solutions.

Key Points: 
  • This release marks significant progress in the development of ChromaCode's software, ensuring accessibility, affordability, and security in laboratory-based diagnostic solutions.
  • ChromaCode Cloud is an advanced analysis platform supporting real-time and digital PCR assays.
  • The software empowers users to optimize analysis configurations seamlessly, with the cloud-based framework eliminating the need for local hardware or software installation.
  • Stringent Regulatory Compliance: ChromaCode Cloud has achieved HITRUST Implemented, i1 certification again this year, reaffirming its commitment to data security.

Coherus Announces U.S. Launch of LOQTORZI™

Retrieved on: 
Dienstag, Januar 2, 2024
DCR, Platinum, NPC, Partnership, Neoplasm, Nasopharyngeal carcinoma, Survival, ABC, Immune system, Risk, CHRS, Prognosis, McKesson Corporation, FDA, PD-1, Hope, Progression-free survival, NCCN, Research, Education, Cisplatin, HCPCS, Cancer, Sarcoma, Death, Cardinal, Patient, OS, PFS, NDC, PD-L1, Pharmaceutical industry

REDWOOD CITY, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that LOQTORZI™ (toripalimab-tpzi) is now available through select specialty distributors in the United States. LOQTORZI is indicated in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC), and as monotherapy for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy. LOQTORZI is a next-generation, programmed death receptor-1 (PD-1) monoclonal antibody that blocks PD-1 ligands PD-L1 and PD-L2 with high potency at a unique site on the PD-1 receptor, enabling the immune system to activate and kill the tumor.

Key Points: 
  • In December, the NCCN committee classified LOQTORZI as a preferred category 1 treatment option in combination with gemcitabine and cisplatin.
  • LOQTORZI has demonstrated impressive clinical benefits, including PFS and OS, offering R/M NPC patients new hope for extended survival,” said Paul Reider, Chief Commercial Officer of Coherus.
  • Contact Coherus BioSciences Customer Services at 1-844-562-6004 for more information.
  • Coherus expects a product-specific, permanent J-code to be assigned to LOQTORZI in mid-2024.